aspirin has been researched along with Gestational Hypertension in 62 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the impact of low-dose aspirin (LDA) starting in early pregnancy on delaying preterm hypertensive disorders of pregnancy." | 9.69 | Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial. ( Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Lokangaka, A; McClure, EM; Metgud, MC; Moore, J; Mwenechanya, M; Nielsen, E; Patel, A; Saleem, S; Silver, R; Somannavar, MS; Tshefu, A, 2023) |
| "This study aimed to compare how low-dose aspirin differentially benefits nulliparous women with and without additional preeclampsia risk factors for the prevention of preterm birth and hypertensive disorders of pregnancy." | 9.69 | The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 9.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth." | 9.41 | Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 9.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation." | 9.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| "The comparison of clinical outcome showed that the incidents of pregnancy-induced hypertension syndrome, pre-eclampsia and eclampsia of aspirin group were significantly lower than that of the placebo group (p<0." | 9.22 | Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients. ( Li, L; Liu, FM; Wang, M; Yang, HL; Zhao, M, 2016) |
| "This pilot trial demonstrates that both furosemide and amlodipine might have the same effect during pregnancy." | 9.19 | Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. ( Dominguez, L; Solis, A; Vigil-De Gracia, P, 2014) |
| "The incidence of hypertensive complications was significantly lower in the group of women treated with low-dose aspirin throughout IVF treatment and first trimester of pregnancy." | 9.14 | Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. ( Groeneveld, E; Homburg, R; Hompes, PG; Hoozemans, DA; Lambalk, CB; Lambers, MJ; Schats, R, 2009) |
| "In the present study, the incidence of hypertensive pregnancy complications did not differ statistically significantly between low-dose aspirin and placebo groups in unselected IVF/ICSI patients, when medication was started concomitantly with gonadotrophin stimulation and continued until delivery." | 9.14 | Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. ( Haapsamo, M; Heinonen, S; Martikainen, H; Nuojua-Huttunen, S; Räsänen, J; Tinkanen, H, 2010) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 9.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| "Delivery after US Preventive Services Taskforce aspirin guideline publication was associated with higher rates of hypertensive disorders of pregnancy and preterm birth in a population of individuals with diabetes mellitus." | 8.31 | Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023) |
| "The objective of this study is to investigate possible changes in aspirin resistance during and after pregnancy over time." | 7.96 | Resistance of aspirin during and after pregnancy: A longitudinal cohort study. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A, 2020) |
| "To elucidate patients' knowledge and counseling perspective on aspirin reducing the risk of hypertensive disorders of pregnancy (HDP)." | 7.96 | Patients' perspective on aspirin during pregnancy: a survey. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Groot, C; de Vries, JIP, 2020) |
| "The effect and safety of magnesium sulfate combined with low-dose aspirin in the treatment of pregnancy induced hypertension were assessed by summarizing the related randomized controlled trials." | 7.96 | Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis. ( Chen, M; Chen, Y; He, G; Liu, X, 2020) |
| "Aspirin use in pregnancy reduces the risks of maternal hypertensive disorders." | 7.91 | Aspirin use during pregnancy and hypertensive disorders in women with various risks. ( Chen, C; Jing, S; Lu, D; Xie, H; Zhang, J; Zhu, J, 2019) |
| "To determine whether hypertensive disorders of pregnancy (HDP) increased long-term stroke risk in women in the California Teachers Study (CTS), a prospective cohort study, and whether aspirin or statin use modified this risk." | 7.91 | Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy. ( Bello, NA; Boehme, AK; Chung, NT; Elkind, MSV; Lacey, JV; Lakshminarayan, K; Miller, EC; Wang, SS; Wapner, R; Willey, JZ; Woo, D; Zhong, C, 2019) |
| "Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia." | 7.88 | ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. ( , 2018) |
| "Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia." | 7.88 | ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy. ( , 2018) |
| "The FRUIT-RCT concluded that low-molecular-weight heparin added to aspirin compared to treatment with aspirin alone is beneficial in the prevention of early-onset hypertensive disorders of pregnancy (HD) in women with inheritable thrombophilia and prior HD and/or a small-for-gestational age (SGA) infant leading to delivery before 34 weeks gestation." | 7.85 | Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. ( Abheiden, CNH; Arduç, A; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A; van Diemen, JJK, 2017) |
| "Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality." | 5.72 | Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022) |
| "To assess the impact of low-dose aspirin (LDA) starting in early pregnancy on delaying preterm hypertensive disorders of pregnancy." | 5.69 | Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial. ( Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Lokangaka, A; McClure, EM; Metgud, MC; Moore, J; Mwenechanya, M; Nielsen, E; Patel, A; Saleem, S; Silver, R; Somannavar, MS; Tshefu, A, 2023) |
| "This study aimed to compare how low-dose aspirin differentially benefits nulliparous women with and without additional preeclampsia risk factors for the prevention of preterm birth and hypertensive disorders of pregnancy." | 5.69 | The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023) |
| "Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth." | 5.41 | Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023) |
| "Low-molecular-weight heparin, vitamin D supplementation, exercise, calcium supplementation, and aspirin reduce the risk of preeclampsia/pregnancy-induced hypertension." | 5.41 | Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials. ( Chen, JY; Duan, CY; He, PC; Li, JQ; Liu, YH; Liu, YX; Lye, S; Tan, N; Wang, ZJ; Wei, YX; Xie, NJ; Xu, XJ; Zhang, YS, 2023) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 5.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 5.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "The comparison of clinical outcome showed that the incidents of pregnancy-induced hypertension syndrome, pre-eclampsia and eclampsia of aspirin group were significantly lower than that of the placebo group (p<0." | 5.22 | Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients. ( Li, L; Liu, FM; Wang, M; Yang, HL; Zhao, M, 2016) |
| "To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation." | 5.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| " The following were consistently recommended: (1) automated blood pressure measurement with devices validated for pregnancy and preeclampsia, reflecting increasing recognition of the prevalence of white-coat hypertension and the potential usefulness of home blood pressure monitoring; (2) use of dipstick proteinuria testing for screening followed by quantitative testing by urinary protein-to-creatinine ratio or 24-hour urine collection; (3) key definitions and most aspects of classification, including a broad definition of preeclampsia (which includes proteinuria and maternal end-organ dysfunction, including headache and visual symptoms and laboratory abnormalities of platelets, creatinine, or liver enzymes) and a recognition that it can worsen after delivery; (4) preeclampsia prevention with aspirin; (5) treatment of severe hypertension, most commonly with intravenous labetalol, oral nifedipine, or intravenous hydralazine; (6) treatment for nonsevere hypertension when undertaken, with oral labetalol (in particular), methyldopa, or nifedipine, with recommendations against the use of renin-angiotensin-aldosterone inhibitors; (7) magnesium sulfate for eclampsia treatment and prevention among women with "severe" preeclampsia; (8) antenatal corticosteroids for preterm birth but not hemolysis, elevated liver enzymes, and low platelet count syndrome; (9) delivery at term for preeclampsia; (10) a focus on usual labor and delivery care but avoidance of ergometrine; and (11) an appreciation that long-term health complications are increased in incidence, mandating lifestyle change and risk factor modification." | 5.22 | Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension. ( Gillon, TE; Magee, LA; Pels, A; Scott, G; von Dadelszen, P, 2022) |
| "This pilot trial demonstrates that both furosemide and amlodipine might have the same effect during pregnancy." | 5.19 | Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. ( Dominguez, L; Solis, A; Vigil-De Gracia, P, 2014) |
| "The incidence of hypertensive complications was significantly lower in the group of women treated with low-dose aspirin throughout IVF treatment and first trimester of pregnancy." | 5.14 | Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. ( Groeneveld, E; Homburg, R; Hompes, PG; Hoozemans, DA; Lambalk, CB; Lambers, MJ; Schats, R, 2009) |
| "In the present study, the incidence of hypertensive pregnancy complications did not differ statistically significantly between low-dose aspirin and placebo groups in unselected IVF/ICSI patients, when medication was started concomitantly with gonadotrophin stimulation and continued until delivery." | 5.14 | Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. ( Haapsamo, M; Heinonen, S; Martikainen, H; Nuojua-Huttunen, S; Räsänen, J; Tinkanen, H, 2010) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 5.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| "Delivery after US Preventive Services Taskforce aspirin guideline publication was associated with higher rates of hypertensive disorders of pregnancy and preterm birth in a population of individuals with diabetes mellitus." | 4.31 | Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023) |
| "To elucidate patients' knowledge and counseling perspective on aspirin reducing the risk of hypertensive disorders of pregnancy (HDP)." | 3.96 | Patients' perspective on aspirin during pregnancy: a survey. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Groot, C; de Vries, JIP, 2020) |
| "The objective of this study is to investigate possible changes in aspirin resistance during and after pregnancy over time." | 3.96 | Resistance of aspirin during and after pregnancy: A longitudinal cohort study. ( Abheiden, CNH; Bij de Weg, JM; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A, 2020) |
| "The effect and safety of magnesium sulfate combined with low-dose aspirin in the treatment of pregnancy induced hypertension were assessed by summarizing the related randomized controlled trials." | 3.96 | Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis. ( Chen, M; Chen, Y; He, G; Liu, X, 2020) |
| "To determine whether hypertensive disorders of pregnancy (HDP) increased long-term stroke risk in women in the California Teachers Study (CTS), a prospective cohort study, and whether aspirin or statin use modified this risk." | 3.91 | Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy. ( Bello, NA; Boehme, AK; Chung, NT; Elkind, MSV; Lacey, JV; Lakshminarayan, K; Miller, EC; Wang, SS; Wapner, R; Willey, JZ; Woo, D; Zhong, C, 2019) |
| "Calcium and low-dose aspirin are two potential approaches for primary prevention of hypertensive disorders of pregnancy (HDP)." | 3.91 | Views and preferences of medical professionals and pregnant women about a novel primary prevention intervention for hypertensive disorders of pregnancy: a qualitative study. ( Bekker, MN; Browne, JL; Crombag, NMT; Franx, A; Grobbee, DE; van der Graaf, R; Vestering, A, 2019) |
| "Aspirin use in pregnancy reduces the risks of maternal hypertensive disorders." | 3.91 | Aspirin use during pregnancy and hypertensive disorders in women with various risks. ( Chen, C; Jing, S; Lu, D; Xie, H; Zhang, J; Zhu, J, 2019) |
| "To use the Theory of Planned Behavior (TPB) combined with action and coping planning plus global relationship with husband to explain the aspirin adherence in a sample of women with high-risk pregnancy." | 3.88 | Using extended theory of planned behavior to understand aspirin adherence in pregnant women. ( Broström, A; Lin, CY; Nilsen, P; Pakpour, AH, 2018) |
| "Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia." | 3.88 | ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy. ( , 2018) |
| "Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia." | 3.88 | ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. ( , 2018) |
| "The FRUIT-RCT concluded that low-molecular-weight heparin added to aspirin compared to treatment with aspirin alone is beneficial in the prevention of early-onset hypertensive disorders of pregnancy (HD) in women with inheritable thrombophilia and prior HD and/or a small-for-gestational age (SGA) infant leading to delivery before 34 weeks gestation." | 3.85 | Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. ( Abheiden, CNH; Arduç, A; de Boer, MA; de Vries, JIP; Fuijkschot, WW; Harmsze, AM; Thijs, A; van Diemen, JJK, 2017) |
| "This prospective study aimed to evaluate pregnancy outcome and complications in women with recurrent pregnancy loss (RPL) and protein S (PS) deficiency, who received low dose aspirin (LDA) or LDA plus heparin (LDA/H) therapies." | 3.83 | Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. ( Deguchi, M; Ebina, Y; Morizane, M; Shinozaki, N; Tanimura, K; Yamada, H, 2016) |
| "Aspirin reduces the risk of recurrent hypertensive disorders of pregnancy (HD) and fetal growth restriction (FGR)." | 3.83 | Aspirin adherence during high-risk pregnancies, a questionnaire study. ( Abheiden, CN; de Boer, MA; de Vries, JI; Fuijkschot, WW; Thijs, A; van Reuler, AV, 2016) |
| "The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders." | 3.77 | Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011) |
| "Preeclampsia and gestational hypertension are common pregnancy complications associated with adverse maternal and child outcomes." | 3.01 | Polygenic prediction of preeclampsia and gestational hypertension. ( Antopia, MC; Bhatta, L; Brumpton, BM; Cho, SMJ; Do, R; Gray, KJ; Guerrero, RF; Gupta, RM; Haas, DM; Honigberg, MC; Khan, RR; Koyama, S; Laisk, T; Martin, HC; Nadkarni, GN; Natarajan, P; Patel, AP; Patil, S; Pe'er, I; Saxena, R; Schuermans, A; Selvaraj, MS; Trinder, M; Truong, B; Urbut, SM; van Heel, DA; Vellarikkal, SK; Verma, SS; Vy, HMT; Xiao, B; Yan, Q; Zöllner, S, 2023) |
| "Preeclampsia and gestational hypertension are common complications of pregnancy associated with significant maternal and infant morbidity." | 2.94 | Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension. ( Andriessen, VC; Connell, M; Kim, K; Mendola, P; Mumford, SL; Nobles, CJ; Perkins, NJ; Schisterman, EF; Silver, RM; Sjaarda, L, 2020) |
| "Hemorrhagic stroke is the most common type of obstetric stroke." | 2.72 | Stroke in Pregnancy: A Multidisciplinary Approach. ( Camargo, EC; Singhal, AB, 2021) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| " Avoidance of nephrotoxic and teratogenic medications is necessary, and renal dosing of commonly used medications must also be considered." | 2.61 | Chronic Kidney Disease and Pregnancy. ( Hladunewich, MA; Hui, D, 2019) |
| "Documentation of preeclampsia risk factors: multifetal gestation, pregestational diabetes, chronic hypertension (high-risk factors) and nulliparity, a body mass index greater than 30, African American race, a maternal age 35 years or older, an interval of more than 10-years since last birth, and having low socioeconomic status (moderate risk factors)." | 1.72 | Estimated Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in 2019. ( Myers, ER; Myers, SO; Swamy, GK; Wheeler, SM, 2022) |
| "Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality." | 1.72 | Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022) |
| "Analyze secular trends of preeclampsia in Norway based on risk factors." | 1.72 | Substantial decrease in preeclampsia prevalence and risk over two decades: A population-based study of 1,153,227 deliveries in Norway. ( Laine, K; Räisänen, S; Sole, KB; Staff, AC, 2022) |
| "Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis." | 1.56 | Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. ( Afshar, Y; Bromley, B; Caughey, AB; Chescheir, N; Copel, JA; Grechukhina, O; Grobman, W; Han, CS; Hobbins, JC; Mallampati, D; Nicolaides, K; Pettker, C; Platt, LD; Saade, G; Sibai, B; Simhan, H; Sonek, J; Werner, E, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.23) | 29.6817 |
| 2010's | 32 (51.61) | 24.3611 |
| 2020's | 28 (45.16) | 2.80 |
| Authors | Studies |
|---|---|
| Wheeler, SM | 1 |
| Myers, SO | 1 |
| Swamy, GK | 1 |
| Myers, ER | 1 |
| Sole, KB | 1 |
| Staff, AC | 1 |
| Räisänen, S | 1 |
| Laine, K | 1 |
| Olson, DN | 1 |
| Russell, T | 1 |
| Ranzini, AC | 1 |
| Pathiraja, PDM | 1 |
| Alrub, NA | 1 |
| Sunanda, G | 1 |
| Liu, YH | 1 |
| Zhang, YS | 1 |
| Chen, JY | 1 |
| Wang, ZJ | 1 |
| Liu, YX | 1 |
| Li, JQ | 1 |
| Xu, XJ | 1 |
| Xie, NJ | 1 |
| Lye, S | 1 |
| Tan, N | 1 |
| Duan, CY | 1 |
| Wei, YX | 1 |
| He, PC | 1 |
| D'Antonio, F | 3 |
| Khalil, A | 3 |
| Rizzo, G | 3 |
| Fichera, A | 3 |
| Herrera, M | 3 |
| Buca, D | 3 |
| Morelli, R | 3 |
| Cerra, C | 3 |
| Orabona, R | 3 |
| Acuti Martellucci, C | 3 |
| Flacco, ME | 3 |
| Prefumo, F | 3 |
| Bruno, AM | 1 |
| Allshouse, AA | 1 |
| Metz, TD | 1 |
| Theilen, LH | 2 |
| Kou, X | 1 |
| Yang, J | 1 |
| Honigberg, MC | 1 |
| Truong, B | 1 |
| Khan, RR | 1 |
| Xiao, B | 1 |
| Bhatta, L | 1 |
| Vy, HMT | 1 |
| Guerrero, RF | 1 |
| Schuermans, A | 1 |
| Selvaraj, MS | 1 |
| Patel, AP | 1 |
| Koyama, S | 1 |
| Cho, SMJ | 1 |
| Vellarikkal, SK | 1 |
| Trinder, M | 1 |
| Urbut, SM | 1 |
| Gray, KJ | 1 |
| Brumpton, BM | 1 |
| Patil, S | 1 |
| Zöllner, S | 1 |
| Antopia, MC | 1 |
| Saxena, R | 1 |
| Nadkarni, GN | 1 |
| Do, R | 1 |
| Yan, Q | 1 |
| Pe'er, I | 1 |
| Verma, SS | 1 |
| Gupta, RM | 1 |
| Haas, DM | 1 |
| Martin, HC | 1 |
| van Heel, DA | 1 |
| Laisk, T | 1 |
| Natarajan, P | 1 |
| Bangi, EF | 1 |
| Yousuf, MH | 1 |
| Upadhyay, S | 1 |
| Jain, P | 1 |
| Jain, R | 1 |
| Kavi, A | 2 |
| Hoffman, MK | 2 |
| Somannavar, MS | 1 |
| Metgud, MC | 1 |
| Goudar, SS | 2 |
| Moore, J | 2 |
| Nielsen, E | 1 |
| Goco, N | 2 |
| McClure, EM | 2 |
| Lokangaka, A | 2 |
| Tshefu, A | 2 |
| Bauserman, M | 2 |
| Mwenechanya, M | 1 |
| Chomba, E | 2 |
| Carlo, WA | 2 |
| Figueroa, L | 2 |
| Krebs, NF | 2 |
| Jessani, S | 2 |
| Saleem, S | 2 |
| Goldenberg, RL | 2 |
| Das, P | 2 |
| Patel, A | 1 |
| Hibberd, PL | 2 |
| Esamai, F | 2 |
| Bucher, S | 2 |
| Koso-Thomas, M | 1 |
| Silver, R | 1 |
| Derman, RJ | 2 |
| Nuss, EE | 1 |
| Metgud, M | 1 |
| Somannavar, M | 1 |
| Okitawutshu, J | 1 |
| Tembo, AM | 1 |
| Kurhe, K | 1 |
| Achieng, E | 1 |
| Nyongesa, P | 1 |
| Liechty, EA | 1 |
| Hemingway-Foday, J | 1 |
| Silver, RM | 3 |
| Chen, WY | 1 |
| Sun, SF | 1 |
| Zhu, J | 1 |
| Chen, C | 1 |
| Lu, D | 1 |
| Zhang, J | 2 |
| Jing, S | 1 |
| Xie, H | 1 |
| Copel, JA | 1 |
| Platt, LD | 1 |
| Hobbins, JC | 1 |
| Afshar, Y | 1 |
| Grechukhina, O | 1 |
| Mallampati, D | 1 |
| Bromley, B | 1 |
| Caughey, AB | 2 |
| Grobman, W | 1 |
| Han, CS | 1 |
| Nicolaides, K | 1 |
| Pettker, C | 1 |
| Saade, G | 1 |
| Sibai, B | 1 |
| Simhan, H | 1 |
| Sonek, J | 1 |
| Werner, E | 1 |
| Chescheir, N | 1 |
| Bij de Weg, JM | 2 |
| Abheiden, CNH | 3 |
| Fuijkschot, WW | 3 |
| Harmsze, AM | 2 |
| de Boer, MA | 5 |
| Thijs, A | 3 |
| de Vries, JIP | 3 |
| Ekawati, FM | 1 |
| Emilia, O | 1 |
| Brennecke, S | 1 |
| Gunn, J | 1 |
| Licqurish, S | 1 |
| Lau, P | 1 |
| Campbell, HD | 1 |
| Mumford, SL | 2 |
| Purdue-Smithe, AC | 1 |
| Sjaarda, LA | 1 |
| Perkins, NJ | 2 |
| Radoc, JG | 1 |
| Schisterman, EF | 2 |
| Ghazanfarpour, M | 1 |
| Sathyapalan, T | 1 |
| Banach, M | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Ramlakhan, KP | 1 |
| Johnson, MR | 1 |
| Roos-Hesselink, JW | 1 |
| de Groot, C | 1 |
| Gibson, KS | 1 |
| Hameed, AB | 1 |
| Nobles, CJ | 1 |
| Mendola, P | 1 |
| Kim, K | 1 |
| Andriessen, VC | 1 |
| Connell, M | 1 |
| Sjaarda, L | 1 |
| Scott, G | 1 |
| Gillon, TE | 1 |
| Pels, A | 1 |
| von Dadelszen, P | 2 |
| Magee, LA | 2 |
| Lanssens, D | 1 |
| Thijs, IM | 1 |
| Gyselaers, W | 1 |
| Booker, WA | 1 |
| He, G | 2 |
| Chen, Y | 1 |
| Chen, M | 1 |
| Liu, X | 1 |
| Camargo, EC | 1 |
| Singhal, AB | 1 |
| Xiang, X | 1 |
| Wang, F | 1 |
| Zhao, N | 1 |
| Zhou, Z | 1 |
| Jackson, JR | 1 |
| Gregg, AR | 1 |
| Iriye, BK | 1 |
| Gregory, KD | 1 |
| Saade, GR | 1 |
| Grobman, WA | 1 |
| Brown, HL | 1 |
| Lin, CY | 1 |
| Broström, A | 1 |
| Nilsen, P | 1 |
| Pakpour, AH | 1 |
| Chahine, KM | 1 |
| Sibai, BM | 1 |
| Miller, EC | 1 |
| Boehme, AK | 1 |
| Chung, NT | 1 |
| Wang, SS | 1 |
| Lacey, JV | 1 |
| Lakshminarayan, K | 1 |
| Zhong, C | 1 |
| Woo, D | 1 |
| Bello, NA | 1 |
| Wapner, R | 1 |
| Elkind, MSV | 1 |
| Willey, JZ | 1 |
| Feske, SK | 1 |
| Bushnell, C | 2 |
| Leavitt, K | 1 |
| Običan, S | 1 |
| Yankowitz, J | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Vestering, A | 1 |
| Bekker, MN | 1 |
| Grobbee, DE | 1 |
| van der Graaf, R | 1 |
| Franx, A | 1 |
| Crombag, NMT | 1 |
| Browne, JL | 1 |
| Hui, D | 1 |
| Hladunewich, MA | 1 |
| Groeneveld, E | 2 |
| Lambers, MJ | 2 |
| Lambalk, CB | 2 |
| Broeze, KA | 1 |
| Haapsamo, M | 2 |
| de Sutter, P | 1 |
| Schoot, BC | 1 |
| Schats, R | 2 |
| Mol, BW | 1 |
| Hompes, PG | 2 |
| Vigil-De Gracia, P | 1 |
| Dominguez, L | 1 |
| Solis, A | 1 |
| van Hoorn, ME | 1 |
| Hague, WM | 1 |
| van Pampus, MG | 1 |
| Bezemer, D | 1 |
| de Vries, JI | 3 |
| Shinozaki, N | 1 |
| Ebina, Y | 1 |
| Deguchi, M | 1 |
| Tanimura, K | 1 |
| Morizane, M | 1 |
| Yamada, H | 1 |
| Bartsch, E | 1 |
| Medcalf, KE | 1 |
| Park, AL | 1 |
| Ray, JG | 1 |
| Helou, A | 1 |
| Walker, S | 1 |
| Stewart, K | 1 |
| George, J | 1 |
| Abheiden, CN | 2 |
| Blomjous, BS | 1 |
| Kroese, SJ | 1 |
| Bultink, IE | 1 |
| Fritsch-Stork, RD | 1 |
| Lely, AT | 1 |
| van Reuler, AV | 1 |
| Liu, FM | 1 |
| Zhao, M | 1 |
| Wang, M | 1 |
| Yang, HL | 1 |
| Li, L | 1 |
| Arduç, A | 1 |
| van Diemen, JJK | 1 |
| Hoozemans, DA | 1 |
| Homburg, R | 1 |
| Martikainen, H | 1 |
| Tinkanen, H | 1 |
| Heinonen, S | 1 |
| Nuojua-Huttunen, S | 1 |
| Räsänen, J | 1 |
| Graham, DF | 1 |
| Hadlow, N | 1 |
| Tsokos, N | 1 |
| Oates, R | 1 |
| Ismail, SK | 1 |
| Higgins, JR | 1 |
| Morales-Vidal, S | 1 |
| Schneck, MJ | 1 |
| Flaster, MS | 1 |
| Biller, J | 1 |
| Tate, J | 1 |
| Bujold, E | 1 |
| Pasquier, JC | 1 |
| Bakhti, A | 1 |
| Vaiman, D | 1 |
| Ames, M | 1 |
| Rueda, J | 1 |
| Vainio, M | 1 |
| Riutta, A | 1 |
| Koivisto, AM | 1 |
| Mäenpää, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.[NCT00467363] | 1,228 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| PREMOM II: Pregnancy Remote Monitoring of Women With Gestational Hypertensive Disorders[NCT04031430] | 6,107 participants (Anticipated) | Interventional | 2019-06-18 | Recruiting | |||
| STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY: Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy (CRISP STUDY)[NCT04767438] | 6,560 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
| A Pragmatic Randomized Study Comparing 81 mg Aspirin Versus 162 mg Aspirin in the Prevention of Preeclampsia During Pregnancy[NCT04158830] | Phase 4 | 0 participants (Actual) | Interventional | 2020-06-01 | Withdrawn (stopped due to PI is no longer at this University.) | ||
| 162 mg of Aspirin for Prevention of Preeclampsia[NCT05221164] | Phase 4 | 200 participants (Anticipated) | Interventional | 2021-07-06 | Recruiting | ||
| Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial[NCT05802940] | 640 participants (Anticipated) | Interventional | 2023-06-19 | Not yet recruiting | |||
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
| Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.[NCT02174328] | Phase 3 | 81 participants (Actual) | Interventional | 2014-05-21 | Terminated (stopped due to Halted prematurely due to low recruitment rate.) | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Assessment of the Cardiovascular Risk Profile of Infants Exposed to Pre-eclampsia in Utero[NCT05091827] | 234 participants (Anticipated) | Observational | 2021-11-30 | Not yet recruiting | |||
| A Randomized Controlled Trial Comparing Low Doses Of Aspirin In The Prevention Of Preeclampsia (ASAPP)[NCT04070573] | Phase 3 | 400 participants (Anticipated) | Interventional | 2019-10-21 | Enrolling by invitation | ||
| The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study[NCT00683202] | 374 participants (Actual) | Interventional | 2001-03-31 | Completed | |||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Partial or complete abruption (ie, premature separation of the placenta) (NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 7 |
| Placebo | 5 |
(NCT00467363)
Timeframe: 8-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 374 |
| Placebo | 346 |
Implantation failures (NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 28 |
| Placebo | 27 |
(NCT00467363)
Timeframe: within 6 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 3 |
| Placebo | 3 |
(NCT00467363)
Timeframe: until 40 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 4 |
| Placebo | 6 |
(NCT00467363)
Timeframe: within 8-weeks of gestation
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 394 |
| Placebo | 363 |
Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff . (NCT00467363)
Timeframe: after delivery
| Intervention | livebirths (Number) |
|---|---|
| Aspirin | 309 |
| Placebo | 286 |
(NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 0 |
| Placebo | 0 |
(NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 32 |
| Placebo | 30 |
Includes preembryonic and embryonic losses (exclusive of implantation failures) (NCT00467363)
Timeframe: less than 10-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 56 |
| Placebo | 53 |
(NCT00467363)
Timeframe: until delivery
| Intervention | infants (Number) |
|---|---|
| Aspirin | 22 |
| Placebo | 31 |
birthweight (NCT00467363)
Timeframe: until delivery
| Intervention | grams (Mean) |
|---|---|
| Aspirin | 3327 |
| Placebo | 3315 |
(NCT00467363)
Timeframe: 40 weeks
| Intervention | participants (Number) |
|---|---|
| Aspirin | 2 |
| Placebo | 2 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
21 reviews available for aspirin and Gestational Hypertension
| Article | Year |
|---|---|
Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials.
Topics: Aspirin; Bayes Theorem; Calcium; Female; Heparin, Low-Molecular-Weight; Humans; Hypertension, Pregna | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Polygenic prediction of preeclampsia and gestational hypertension.
Topics: Aspirin; Child; Eclampsia; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Pre-Eclamp | 2023 |
Comprehensive Review of Hypertensive Disorders Related to Pregnancy.
Topics: Aspirin; Eclampsia; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Placenta; Pre- | 2023 |
Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis.
Topics: Aspirin; Calcium; Calcium, Dietary; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn | 2023 |
Opportunities for improving hypertensive disorders of pregnancy (HDP) management in primary care settings: A review of international published guidelines in the context of pregnancy care in Indonesia.
Topics: Aspirin; Calcium; Calcium-Regulating Hormones and Agents; Communication; Female; General Practice; H | 2020 |
Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Hemorrhage; Humans; Hypertension, Pre | 2020 |
Pregnancy and cardiovascular disease.
Topics: Acute Coronary Syndrome; Antihypertensive Agents; Aortic Dissection; Arrhythmias, Cardiac; Aspirin; | 2020 |
Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Calcium; Delivery, Obstetric; Female; Glucocortic | 2022 |
Hypertensive Disorders of Pregnancy.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Chronic Disease; Delivery, Obstetric; Eclampsia; | 2020 |
Stroke in Pregnancy: A Multidisciplinary Approach.
Topics: Aspirin; Brain Diseases; Cardiomyopathies; Cesarean Section; Eclampsia; Embolism, Paradoxical; Femal | 2021 |
Updates on the Recognition, Prevention and Management of Hypertension in Pregnancy.
Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregation Inhibitors; Pregnancy | 2017 |
Treatment and Prevention of Hypertensive Disorders During Pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Chronic Dis | 2019 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Chronic Kidney Disease and Pregnancy.
Topics: Aspirin; Female; Glomerular Filtration Rate; Humans; Hypertension, Pregnancy-Induced; Infant, Newbor | 2019 |
Preconceptional low-dose aspirin for the prevention of hypertensive pregnancy complications and preterm delivery after IVF: a meta-analysis with individual patient data.
Topics: Adult; Aspirin; Female; Fertilization in Vitro; Humans; Hypertension, Pregnancy-Induced; Logistic Mo | 2013 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Preventing deaths due to the hypertensive disorders of pregnancy.
Topics: Aspirin; Birth Intervals; Calcium; Cardiotocography; Dietary Supplements; Eclampsia; Female; Food Su | 2016 |
Hemostasis in pre-eclampsia.
Topics: Aspirin; Female; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Hypertension, Pregnancy-Induced; | 2011 |
Pregnancy and stroke risk in women.
Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnancy-Induced; Plate | 2011 |
Ambulatory management of chronic hypertension in pregnancy.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Disease | 2012 |
12 trials available for aspirin and Gestational Hypertension
| Article | Year |
|---|---|
Labetalol, Low-dose Aspirin, and Vitamin E and Calcium for Gestational Hypertension and Influence on MicroRNA-126 and PLGF Levels.
Topics: Aspirin; Calcium; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; MicroRNA | 2023 |
Aspirin delays the onset of hypertensive disorders of pregnancy among nulliparous pregnant women: A secondary analysis of the ASPIRIN trial.
Topics: Aspirin; Child; Child Health; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Indu | 2023 |
The impact of risk factors on aspirin's efficacy for the prevention of preterm birth.
Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Male; Perinatal Death; Pr | 2023 |
Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension.
Topics: Adult; Aspirin; Blood Pressure Determination; Drug Monitoring; Early Diagnosis; Female; Humans; Hype | 2020 |
Design of the Pregnancy REmote MOnitoring II study (PREMOM II): a multicenter, randomized controlled trial of remote monitoring for gestational hypertensive disorders.
Topics: Adult; Aspirin; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Hypertension, Pregnancy-In | 2020 |
Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Do | 2020 |
Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Aspirin; Diuretics; Female; Furosemide; Humans; Hyperten | 2014 |
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co | 2016 |
Effect of regular oral intake of aspirin during pregnancy on pregnancy outcome of high-risk pregnancy-induced hypertension syndrome patients.
Topics: Aspirin; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; Pr | 2016 |
Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy.
Topics: Adult; Aspirin; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypertension, Pregnancy | 2009 |
Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study.
Topics: Adult; Aspirin; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypertension, Pregnancy | 2010 |
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype | 2004 |
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype | 2004 |
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype | 2004 |
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Cyclooxygenase Inhibitors; Epoprostenol; Female; Humans; Hype | 2004 |
29 other studies available for aspirin and Gestational Hypertension
| Article | Year |
|---|---|
Estimated Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in 2019.
Topics: Adult; Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; Prevalenc | 2022 |
Substantial decrease in preeclampsia prevalence and risk over two decades: A population-based study of 1,153,227 deliveries in Norway.
Topics: Aspirin; Cohort Studies; Female; Humans; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; | 2022 |
Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence.
Topics: Aspirin; Autoimmune Diseases; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Pre- | 2022 |
Indications for commencing aspirin for the prevention of pregnancy-induced hypertension and pre-eclampsia spectrum disorders.
Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy | 2022 |
Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus.
Topics: Aspirin; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension, Pregnancy-Induced | 2023 |
Aspirin use during pregnancy and hypertensive disorders in women with various risks.
Topics: Adult; Aspirin; China; Cohort Studies; Female; Humans; Hypertension, Pregnancy-Induced; Platelet Agg | 2019 |
Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary.
Topics: Aspirin; Consensus; Cost-Benefit Analysis; Female; Gestational Age; Humans; Hypertension, Pregnancy- | 2020 |
Resistance of aspirin during and after pregnancy: A longitudinal cohort study.
Topics: Adult; Aspirin; Cohort Studies; Drug Resistance; Female; Humans; Hypertension, Pregnancy-Induced; Lo | 2020 |
Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.
Topics: Abruptio Placentae; Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnanc | 2020 |
Patients' perspective on aspirin during pregnancy: a survey.
Topics: Adult; Aspirin; Female; Health Knowledge, Attitudes, Practice; Humans; Hypertension, Pregnancy-Induc | 2020 |
Society for Maternal-Fetal Medicine Special Statement: Checklist for postpartum discharge of women with hypertensive disorders.
Topics: Aspirin; Blood Pressure Monitoring, Ambulatory; Checklist; Exercise; Female; Humans; Hypertension, P | 2020 |
Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis.
Topics: Aspirin; Clinical Protocols; Female; Humans; Hypertension, Pregnancy-Induced; Magnesium Sulfate; Met | 2020 |
Quality measures in high-risk pregnancies: Executive Summary of a Cooperative Workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists.
Topics: Antibiotic Prophylaxis; Aspirin; Cesarean Section; Congresses as Topic; Female; Fetal Growth Retarda | 2017 |
Using extended theory of planned behavior to understand aspirin adherence in pregnant women.
Topics: Adaptation, Psychological; Adult; Aspirin; Cardiovascular Agents; Female; Health Knowledge, Attitude | 2018 |
ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregati | 2018 |
Chronic Hypertension in Pregnancy: New Concepts for Classification and Management.
Topics: Adult; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Humans; Hypertension; Hypertension | 2019 |
Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy.
Topics: Adult; Age Factors; Aspirin; Female; Fibrinolytic Agents; Follow-Up Studies; Hospitalists; Humans; H | 2019 |
Stroke prevention: How low can you go?
Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Pregnancy; Stroke | 2019 |
Views and preferences of medical professionals and pregnant women about a novel primary prevention intervention for hypertensive disorders of pregnancy: a qualitative study.
Topics: Adult; Aspirin; Attitude of Health Personnel; Calcium; Decision Making; Female; General Practitioner | 2019 |
Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Aspirin; Birth Weight; Comorbidity; Drug Th | 2016 |
Management of pregnancies complicated by hypertensive disorders of pregnancy: Could we do better?
Topics: Adult; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Guideline Adherence; Humans; Hyper | 2017 |
Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Databases, Factual; Female; Heparin, Low- | 2017 |
Aspirin adherence during high-risk pregnancies, a questionnaire study.
Topics: Adult; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Health Knowledge, Attitudes, Practice | 2016 |
Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy.
Topics: Adult; Aspirin; Drug Resistance; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Hypertensio | 2017 |
A case of hypertension with virilisation during pregnancy.
Topics: Adult; Aspirin; Brenner Tumor; Calcium; Cesarean Section; Dehydroepiandrosterone Sulfate; Dietary Su | 2010 |
Stroke- and pregnancy-induced hypertensive syndromes.
Topics: Adult; Antihypertensive Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnanc | 2011 |
Prevention of perinatal death with low-dose aspirin in developing countries.
Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Platelet Aggregation Inhibitors; Pre-Eclam | 2011 |
Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation.
Topics: Adult; Aspirin; Birth Weight; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fetal | 2011 |